Abstract
BACKGROUND: Few studies have focused on the efficacy of stereotactic body radiation therapy (SBRT) in treating early hepatocellular carcinoma (HCC) for curative intention. This study aims to determine the best option among resection, ablation, and SBRT in dealing with single HCC no more than 5 cm. MATERIALS AND METHODS: This multicenter retrospective cohort study included 985 patients from 3 hospitals: 495, 335, and 155 in the resection, ablation, and SBRT groups, respectively, between January 2014 and December 2021. Subgroup analysis and propensity score matching (PSM) were performed. RESULTS: The SBRT group had unfavorable clinical features including larger tumor size, poorer liver function, and more relapsed tumors. The 1-year, 3-year, and 5-year recurrence-free survival (RFS) rates were 84.3%, 66.8%, and 56.2% with resection, 73.3%, 49.8%, and 37.2% with ablation and 73.2%, 56.4%, and 53.6% with SBRT, respectively ( P <0.001). The 3-year overall survival (OS) rates were 89.0%, 89.2%, and 88.8% in the resection, ablation, and SBRT group, respectively ( P =0.590). The three modalities resulted in similar RFS and OS after adjusting for clinical factors. Resection provided ideal local tumor control, successively followed by SBRT and ablation. SBRT led to comparable RFS time compared to resection for tumors <3 cm (HR=0.75, P =0.205), relapsed tumors (HR=0.83, P =0.420), and patients with poor liver function (HR=0.70, P =0.330). In addition, SBRT was superior to ablation regarding RFS when tumors were adjacent to intrahepatic vessels (HR=0.64, P =0.031). SBRT were more minimally invasive, however, gastrointestinal disorders, hepatic inflammation, and myelosuppression occurred more frequently. CONCLUSION: All three approaches could be applied as curative options. Resection remains the best choice for preventing tumor recurrence, and SBRT showed advantages in treating small, recurrent and vascular-type lesions as well as patients with relatively poor liver function.